Clinical trial · Observational
A Population-based, Multicenter Cohort Study of Combined Screening for Gastrointestinal Tumors
NCT05996458CI-TRIAL-00070391recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To establish combined gastroenteroscopy screening and follow-up management for gastrointestinal tumors, explore and evaluate the feasibility and health economic benefits of combined screening for esophagus, stomach and colorectal cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Digestive Disease | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test | Other | — | UNRESOLVED |
| Risk factor investigation; | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- group one
- description
- The screening population will undergo gastroscopy, colonoscopy, fecal occult blood test (FIT), Helicobacter pylori (HP) antigen test, ring finger protein 180 (RNF180) and SEPTIN9 gene methylation test, and investigation of risk factors, including past disease history, alcohol drinking history, smoking history, tea drinking history, family history of cancer, marital and reproductive status, and dietary habits.
- interventionNames
- Other: Gastroenteroscopy；Risk factor investigation; FIT-HP;RNF180 and SEPTIN9 gene methylation test
- label
- Group one's control（Spouse or sibling of group one )
- description
- Only the risk factors will be investigated
- interventionNames
- Other: Risk factor investigation;
- label
- group two
- description
- The screening population will undergo investigation of risk factors, a fecal occult blood test (FIT), and a stool test for Helicobacter pylori (HP) antigen. If a stool occult blood test or H. pylori antigen is positive after testing, RNF180 and SEPTIN9 gene methylation testing will be scheduled. If the gene methylation test is positive, a colonoscopy will be scheduled.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 45 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. Subjects were 45 to 70 years old when enrolled 2. Willing and able to sign informed consent Exclusion Criteria: * 1\. History of any type of malignancy 2. Previous resection of esophagus, stomach or colorectal 3. Received gastrointestinal endoscopy such as colonoscopy and gastroscopy in recent 5 years 4. Have received fecal occult blood test and fecal DNA test in the past 1 year. 5. Contraindications to endoscopy. 6. Warning symptoms of digestive tract tumors, including: 1. Difficulty swallowing, choking or halting feeling when eating recently 2. Recent esophageal foreign body sensation or swallowing pain 3. Recent long-term loss of appetite and appetite 4. Recent and prolonged symptoms of indigestion (including acid reflux, heartburn, abdominal grumbling, burping, nausea or premature satiety, etc.) 5. Recent symptoms of abdominal mass, abdominal pain, vomiting or hematemesis 6. It was medically diagnosed as iron deficiency anemia 7. Recent changes in hematochezia, black stool or stool character and frequency 8. Recent symptoms of perianal discomfort (including soreness, itching, lumps, prolapse or other discomfort) 9. Unexplained weight loss (more than 10% of base body weight) in the past 6 months Step 7 Get pregnant 8. There are other serious comorbiditions that reduce screening benefits (including severe lung disease, advanced kidney disease, advanced liver disease, severe heart failure, etc.)
References
Publications (0)
Data not yet available
No reference posted for this study.